

Cancer Chemotherapy

**Munir Gharaibeh MD, PhD, MHPE
School of Medicine,
The University of Jordan**

Modalities of Cancer Chemotherapy

Curative(شفائي):

Only in 10-15% of cases.

In certain disseminated neoplasms.

Palliative(تسکيني):

Given only to relieve the symptoms temporarily and enhance the overall quality of life, not to cure the cancer.

Adjuvant(مساعد):

Given as an *adjuvant* to surgery, even if there is no evidence of metastasis.

Cancer Chemotherapy

- **Classes of Anticancer Drugs:**
- **Signal Transduction Inhibitors.**
- **Microtubule Inhibitors.**
- **Differentiation agents.**
- **Antimetastatic Drugs.**
- **Antiangiogenic drugs.**
- **Hypoxic Tumor Stem Cell- specific.**
- **Tumor Radiosensitizing.**
- **Normal Tissue Radioprotecting Drugs.**
- **Cytoprotective Agents.**
- **Biologic Response Modifiers.**

The Ideal Anticancer Drugs


- **Exploits the differences between normal and tumor cells.**
- **Broad spectrum of activity.**
- **Good distribution through the body.**
- **Non-immugenic.**
- **Adequate biological half life.**
- **Reasonably priced.**

Current Anticancer Drugs

- **Carcinogenic.**
- **Mutagenic.**
- **Teratogenic.**
- **Immunosuppressive.**
- **Very toxic, but tolerance can develop.**

Gompertzian Tumor Growth

- The growth rate of a tumor is not constant and **peaks** when the tumor is about one **third** of its maximum size.
- Gompertzian growth curve describes the complex pattern of tumor growth. The curve has an early, almost exponential growth rate followed by slower growth rate which reaches a plateau as tumors grow larger in size.



PERCENT OF MAXIMUM VALUE




Fig. 7. Norton-Simon relationship between tumor size (A), instantaneous growth fraction (GF) (B), and growth rate (C) for unperturbed Gompertzian growth. While the GF is maximum at the time of initiation of growth the growth rate is maximum when the tumor is about 37 percent of its limiting size.³ (Reproduced from Cancer Treat Rep.¹³)


Log-Kill Hypothesis (Exponential Cell Kinetics)

In acute leukemias and aggressive lymphomas:

- **Cells at time of diagnosis: 10^{12} .**
- **A very effective drug can kill 99.99%.**
- **So, cells in remission: 10^8 .**
- **Also add, the number of cells that are inherently resistant , cells not available for the drug (CNS, testes), and cells in the G_0 phase.**

LOG kill hypothesis

- The example shows the effects of tumor burden, scheduling, initiation/duration of treatment on patient survival.
- The tumor burden in an untreated patient would progress along the path described by the RED LINE –
- The tumor is detected (using conventional techniques) when the tumor burden reaches 10^9 cells
- The patient is symptomatic at 10^{10} - 10^{11} cells
- Dies at 10^{12} cells.



Combination Therapy

- Anticancer drugs are usually given in combinations to:
 - Increase effectiveness.
 - Reduce the toxicity.
- *Employed to overcome the limited log kill of individual drugs.*
- The drugs should be effective when used as single agents.
- If there is no biochemical basis for synergism, there should be at least additive effects.
- Where possible, drugs with differing modes of actions are combined.

Combination Chemotherapy

- **The major toxicity of each drug, should be as different as possible from that of other agents (non overlapping toxicity).**
- **Toxicity appears at different times.**
- **Myelosuppressant & nonsuppressant.**

Cancer Chemotherapy

- “**Magic bullet**” drug, is a dream that did not materialize yet.
- Cytotoxic drugs are given in repeated courses arranged so that the recovery of normal cells can occur, but little recovery of cancer cells is possible.

Toxicity of Cancer Chemotherapy

- **Cells of the bone marrow, the lymphatic system, and the lining of the intestinal tract are very sensitive to cytotoxic drug effects.**
- **Almost all anticancer drugs cause toxicity, e.g. :**
 - **Bone marrow suppression: Nitrogen mustard.**
 - **Immunosuppression: Methotrexate.**
 - **Neuropathy: Vincristine.**
 - **Cardiotoxicity: Doxorybicin(Adriamycin).**

Special Problems/Practical Points

- **Storage .**
- **Preparation.**
- **Administration.**
- **Extravasation of injection.**
- **Vomiting:**
 - **Lorazepam for anxiety.**
 - **Dexamethasone, Domperidone.**
 - **Ondansetron: 5HT₃ antagonist.**
- **Teratogenesis.**
- **Bone Marrow suppression.**
- **Immunosuppression leading to severe infection.**

Relative Chemosensitivity of Tumors

- **Highly Sensitive:**
- ***May be cured by chemotherapy.***
 - Teratoma of Testis.
 - Hodgkin's and high-grade non- Hodgkin's Lymphomas.
 - Wilms's Tumor.
 - Embryonal Rhabdomyosarcoma.
 - Choriocarcinoma.
 - Acute Lymphoblastic Leukemia in children.
 - Ewing's Sarcoma.

Relative Chemosensitivity of Tumors

- **Moderately Sensitive:**
- ***Chemotherapy may sometimes contribute to cure and often palliates.***
 - Small cell carcinoma of the lung.
 - Breast carcinoma.
 - Low grade non-Hodgkin's Lymphoma.
 - Acute Myeloid Leukemia.
 - Ovarian cancer.
 - Myeloma.

Relative Chemosensitivity of Tumors

- Relatively Insensitive:
- *Chemotherapy may sometimes produce palliation (تسكين).*
 - Gastric carcinoma.
 - Bladder carcinoma.
 - Squamous cell carcinoma of head and neck.
 - Soft tissue sarcoma.
 - Cervical carcinoma.

Relative Chemosensitivity of Tumors

- **Resistant Tumors:**
 - Melanoma.
 - Squamous cell carcinoma of the lung.
 - Large bowel cancer.

Resistance to Cytotoxic Drugs

Primary or Inherent Resistance:

Absence of response on the first exposure.

- Melanoma, renal cell carcinoma, brain cancer.

Acquired Resistance:

1. Highly Specific:

- For one single drug.
- Based on a change in the genetic apparatus of a given tumor cell with amplification or increased expression (*gene amplification*) of one or more specific genes.

Resistance to Cytotoxic Drugs

2. Multidrug-Resistance(Pleiotropic متعدد الاتجاهات):

- Resistance to a variety of natural product anticancer agents of different structures developing after exposure to a single agent.
- Associated with increased expression of a normal gene(*the MDR1gene*) for a cell surface glycoprotein (P-glycoprotein) involved in drug efflux.

Resistance to Cytotoxic Drugs

2. Multidrug-Resistance(Pleiotropic): cont...

- This glycoprotein requires ATP to expel a variety of foreign molecules and not limited to anticancer drugs.
- Reversed by calcium channel blockers.
- Could also be due to overexpression of the multidrug resistance protein1 (MRP1) which can function as a drug export pump.

Resistance to Cytotoxic Drugs

3. Biochemical Resistance:

Decreased drug transport into the cells.

Alteration in the structure of the target enzyme.

Changes in cell DNA repair capability.

Complicatins of Chemotherapy


- **Immediate Complications:**
 - Nausea and vomiting.
 - Mucosal ulcerations.
 - Bone marrow depression.
 - Alopecia.

Complications of Chemotherapy

- **Long term complications:**
 - **Infertility.**
 - **Secondary cancers.**
 - **Pulmonary fibrosis.**
 - **Cardiomyopathy.**
 - **Nerve damage.**
 - **Loss of hearing.**
 - **Renal impairment.**


Cell Cycle

- Cells, normal and cancerous, pass through a series of phases during its life.



Cell Cycle

- **G_0 : Resting phase.**
- **G_1 : Initial phase, enzyme synthesis.**
- **S: DNA synthesis.**
- **G_2 : Synthesis of cellular components required for mitosis.**
- **M: Mitosis, Cell division phase.**



Cell Cycle

- **Cancer cells in the G_0 will be in the resting phase, and they will be least sensitive to chemotherapy.**
- **Cytotoxic drugs interfere with DNA or RNA and thus have profound effects on normal and malignant cells.**

The Cell Cycle and Anticancer Drugs

Many of the effective anticancer drugs exert their action on cells traversing the cell cycle and are called cell cycle–specific **(CCS)** drugs.

A second group of agents called cell cycle–nonspecific **(CCNS)** drugs can kill tumor cells whether they are cycling or resting in the G_0 compartment. CCNS drugs can kill both G_0 and cycling cells (although cycling cells are more sensitive).

Cell-Cycle-Specific Drugs (CCS)

- **Exert their action on cells traversing the cell cycle.**
- **Effective only when large proportion of the cells are proliferating or are in the growth fraction.**

Cell-Cycle-Specific Drugs (CCS)

- **Antimetabolites:**

- Capecitabine.
- Cladribine.
- Cytarabine.
- Fludarabine.
- 5-Fluorouracil(5-FU).
- Gemcitabine.
- 6-Mercaptopurine(6-MP).
- Methotrexate.
- 6-Thioguanine(6-TG).

Cell-Cycle-Specific Drugs (CCS)

- Antitumor Antibiotics:
 - Bleomycin.
- Epipodophyllotoxins:
 - Etoposide.
 - Teniposide.

Cell-Cycle-Specific Drugs (CCS)

- **Taxanes:**
 - Docetaxil.
 - Paclitaxil.
- **Vinca Alkaloids:**
 - Vinblastine.
 - Vincristine.
 - Vinorelbine.

Cell-Cycle-Nonspecific Drugs (CCNS)

- **Can sterilize tumor cells whether they are cycling or resting or resting in the G_0 compartment.**
- **Useful both in low growth fraction solid tumors as well as in high growth fraction tumors.**
- **Bind to cellular DNA and damage these macromolecules.**

Cell-Cycle-Nonspecific Drugs (CCNS)

- **Alkylating Agents:**

- Busulfan.
- Carmustine.
- Cyclophosphamide.
- Lomustine.
- Mechlorethamine.
- Melphalan.
- Thiotepa.

- **Anthracyclines:**

- Daunorubicin.
- Doxorubicin.
- Epirubicin.
- Idarubicin.
- Mitoxantrone.

Cell-Cycle-Nonspecific Drugs (CCNS)

- Antitumor Antibiotics:
 - Dactinomycin.
 - Mitomycin.
- Camptothecins:
 - Irinotecan.
 - Topotecan.
- Platinum Compounds:
 - Carboplatin.
 - Cisplatin.
 - Oxaliplatin.